[{"address1": "4546 El Camino Real", "address2": "Suite B1", "city": "Los Altos", "state": "CA", "zip": "94022", "country": "United States", "phone": "650 284 4433", "fax": "650 397 4433", "website": "https://renovorx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. The company was founded in 2009 and is headquartered in Los Altos, California.", "fullTimeEmployees": 10, "companyOfficers": [{"maxAge": 1, "name": "Dr. Ramtin  Agah M.D.", "age": 57, "title": "Founder, Chairman of Board & Chief Medical Officer", "yearBorn": 1966, "fiscalYear": 2022, "totalPay": 380035, "exercisedValue": 0, "unexercisedValue": 179000}, {"maxAge": 1, "name": "Mr. Shaun R. Bagai", "age": 46, "title": "CEO & Director", "yearBorn": 1977, "fiscalYear": 2022, "totalPay": 717750, "exercisedValue": 0, "unexercisedValue": 315000}, {"maxAge": 1, "name": "Mr. Ronald B. Kocak CPA, CGMA", "age": 66, "title": "VP, Controller and Principal Accounting & Financial Officer", "yearBorn": 1957, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Leesa  Gentry", "age": 53, "title": "Chief Clinical Officer", "yearBorn": 1970, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.66, "open": 1.26, "dayLow": 1.25, "dayHigh": 1.5099, "regularMarketPreviousClose": 1.66, "regularMarketOpen": 1.26, "regularMarketDayLow": 1.25, "regularMarketDayHigh": 1.5099, "beta": 1.119, "forwardPE": -2.357143, "volume": 81362, "regularMarketVolume": 81362, "averageVolume": 90295, "averageVolume10days": 29050, "averageDailyVolume10Day": 29050, "bid": 1.55, "ask": 1.87, "bidSize": 1800, "askSize": 1100, "marketCap": 22211640, "fiftyTwoWeekLow": 0.531, "fiftyTwoWeekHigh": 4.6, "fiftyDayAverage": 1.44434, "twoHundredDayAverage": 1.472455, "currency": "USD", "enterpriseValue": 10889526, "floatShares": 9428743, "sharesOutstanding": 16827000, "sharesShort": 6835, "sharesShortPriorMonth": 7565, "sharesShortPreviousMonthDate": 1706659200, "dateShortInterest": 1709164800, "sharesPercentSharesOut": 0.0004, "heldPercentInsiders": 0.18569, "heldPercentInstitutions": 0.03097, "shortRatio": 0.12, "shortPercentOfFloat": 0.0004, "impliedSharesOutstanding": 16827000, "bookValue": 0.001, "priceToBook": 1320.0, "lastFiscalYearEnd": 1672444800, "nextFiscalYearEnd": 1703980800, "mostRecentQuarter": 1696032000, "netIncomeToCommon": -9161000, "trailingEps": -0.92, "forwardEps": -0.56, "enterpriseToEbitda": -0.924, "52WeekChange": -0.5769231, "SandP52WeekChange": 0.3150251, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "RNXT", "underlyingSymbol": "RNXT", "shortName": "RenovoRx, Inc.", "longName": "RenovoRx, Inc.", "firstTradeDateEpochUtc": 1629984600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "6babfc24-dc5c-3de1-bf9d-2ec73346783e", "messageBoardId": "finmb_236111504", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.32, "targetHighPrice": 7.0, "targetLowPrice": 4.0, "targetMeanPrice": 5.0, "targetMedianPrice": 4.0, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 3, "totalCash": 3226000, "totalCashPerShare": 0.302, "ebitda": -11784500, "quickRatio": 2.01, "currentRatio": 2.193, "returnOnAssets": -1.15406, "returnOnEquity": -2.247, "freeCashflow": -5001125, "operatingCashflow": -9886000, "financialCurrency": "USD", "trailingPegRatio": null}]